Latest News
Cure SMA Awards Grants to Four States to Expediate the Implementation of SMA Newborn Screening
On July 3, 2018, Health and Human Services Secretary Alex Azar approved the recommendation that newborn screening for spinal muscular atrophy be implemented nationwide. This recommendation was issued on February 8, 2018, […]
Read More ›2019 SMA Researcher Meeting Summary: Special Session on Spinal and Neuromuscular Circuitry: Exploring Defects in SMA and Potential Therapeutic Targets
The annual SMA Researcher Meeting is the largest research meeting in the world specifically focused on SMA. This year, we had a record setting 735 attendees join together in Anaheim, […]
Read More ›Cure SMA Update on Data Accuracy Issues with AveXis’ SMA Therapy, Zolgensma
Earlier this week, the FDA issued a statement identifying data accuracy issues with AveXis’ SMA therapy, Zolgensma. Cure SMA immediately opened an investigation into the matter and is committed to […]
Read More ›Cure SMA Releases Status Update on Data Accuracy Issues with Zolgensma
Yesterday, the FDA issued a statement identifying data accuracy issues with Avexis’ SMA therapy, Zolgensma. Cure SMA is in communication with the FDA and is committed to representing the SMA patient voice […]
Read More ›FDA Issues Statement on Data Accuracy Issues with Recently Approved Gene Therapy
Today, the FDA issued the below statement identifying data accuracy issues with AveXis’ SMA therapy, Zolgensma. Cure SMA is investigating this issue and will report when we have further details. We will be […]
Read More ›Biogen Issues Community Statement on Spinraza
Biogen has provided the following community statement on Spinraza. Dear members of the SMA community, Following a busy spring of data presentations at medical congresses and the annual Cure SMA […]
Read More ›